In Addition To Its Influence On Food Intake And Weight
Gain, The Body’s Hormone Ghrelin Is A Sleep-Promoting Factor
New study may have implications for millions in search
of the elusive “good night’s sleep”
March 18, 2003 (Bethesda, MD) -- In movies and
novels alike, much is made of the stage of sleep known as rapid eye movement
(REM), since this is the phase of slumber in which dreams (good, bad,
exotic) occur. Among the medical community, there is an increased
appreciation for what is called “slow-wave” sleep, (also known as deep or
delta-wave sleep), because this fourth stage of sleep can be difficult to
attain. If one is awakened during the first three stages of sleep, they must
repeat these stages again before reaching fourth stage or “delta-wave,”
sleep.
Once this latter stage is reached, muscles are relaxed,
blood pressure drops, and the pulse and breathing are slower. According to
the Sleep Research Center, other benefits to the body are accrued during
slow-wave sleep, including: an increase of blood supply to the body; a
decrease in body temperature thus preserving energy; a lowering of metabolic
activity enabling tissue repair and growth; an increase of natural
immune-system modulators; and a period in which the growth hormone
secretions reach their peak, thus stimulating body growth and development.
A New Study
A team of researchers has found that the
peptide hormone ghrelin, bound to the
growth hormone secretagogue (GHS) receptor, has a distinct positive action
on stage four sleep and nocturnal hormone secretion. Their findings
suggest that, in addition to its influence on growth hormone secretion, food
intake, and weight gain, ghrelin is a sleep-promoting factor. This new role
for the peptide appears to be complementary in function to its established
function in the regulation of energy balance and obesity.
Previous rat studies offered conflicting data on sleep
following ghrelin administration. In one study, a decrease of REM sleep was
found after administration of ghrelin to rats. In another study, ghrelin was
given to two different strains of mice, intact animals and those with
nonfunctional growth hormone-releasing hormone receptors. Only in mice with
intact growth hormone-releasing hormone receptors did NREM sleep increase
after administration of the peptide.
Prior to this research, the influence of ghrelin on
human sleep was unknown. A team of German researchers selected a protocol
that followed previous studies on the sleep-endocrine effects of the
peptide, including growth hormone-releasing hormone, GHRP-6, hexarelin, and
vasoactive intestinal peptide (VIP). They investigated the effects of the
systematic administration of ghrelin on sleep EEG and of GH, ACTH, cortisol,
and leptin in healthy male subjects. The authors of “Ghrelin Promotes
Slow-Wave Sleep in Humans” are J. C. Weikel, A. Wichniak, M. Ising, H.
Brunner, E. Friess, K. Held, S. Mathias, D. A. Schmid, M. Uhr, and A.
Steiger, all from the Max Planck Institute of Psychiatry, Department of
Psychiatry, Munich, Germany. Their findings appear in the February 2003
edition of the American Journal of Physiology-Endocrinology and
Metabolism.
Methodology
Subjects in this study were healthy male volunteers,
all free of alcohol, tobacco, and caffeine abuse. The sleep-endocrine
studies consisted of two sessions, separated by one week in which a placebo
(saline) or ghrelin was administered according to a double-blind, randomized
schedule. The experimental sessions consisted of two successive nights in
the sleep laboratory. The first night allowed adaptation to the laboratory
setting. On the second night, a dose of ghrelin or placebo was administered
as a bolus injection through an indwelling intravenous catheter, which
permitted administration of the testing drug and repeated blood collection
in the adjacent laboratory without disturbing the study subject.
All subjects were reclining at 8:00 PM. Injections of
ghrelin or placebo were given hourly between 10:00 PM and 1:00 AM. Blood
samples were collected every 30 minutes between 8:00 and 10:00 PM, and every
20 minutes between 10:00 PM and 7:00 AM. The subjects were not allowed to
sleep until the lights were turned off at 11:00 PM. Polysomnographic
recordings were obtained from 11:00 PM to 7:00 AM, and consisted of two
EEGs, vertical and horizontal electroculograms, and electromyogram. A
hormone analysis was conducted with the drawn blood samples.
Results
On the night of ghrelin administration, the time spent
in slow-wave or stage IV sleep increased significantly compared with the
placebo night. Separate inspections of the three sleep-time segments showed
significant increases of slow-wave sleep during the first and second thirds
of the night but not during the last third. REM sleep showed a significant
decrease only during the second third of the night. Intermittent wakefulness
appeared to decrease, although it did not reach a level of significance. All
other sleep continuity and sleep architecture variables remained unchanged.
Conclusions
This study finds that the body’s endocrine system may
offer a means for the body to obtain deep sleep, that which contributes to
the body’s overall health. These findings could have important implications
for long-term health, since the pursuit of a “good night’s sleep” is an
obsession for many Americans.
Source: February 2003 edition of the American
Journal of Physiology-Endocrinology and Metabolism.
-end-
The American Physiological
Society (APS) was founded in 1887 to foster basic and applied science, much
of it relating to human health. The Bethesda, MD-based Society has more than
10,000 members and publishes 3,800 articles in its 14 peer-reviewed journals
every year.
***
Editor’s Note: To set up
an interview with a member of the research team, please contact Donna Krupa
at 703.527.7357 (direct dial), 703.967.2751 (cell) or
djkrupa1@aol.com.